Skip to main content
Premium Trial:

Request an Annual Quote

Martin Verhoef and William Rich

Premium

Martin Verhoef, senior vice president for sales, marketing, and operations, will become president of Ciphergen’s new Biosystems division, as well as executive vice president, and will report to William Rich, president and CEO, the company said last week. Verhoef, who has been with Ciphergen since April 2000, will lead the company’s research products group — which sells the company’s ProteinChip systems, arrays, and services — and the bioprocess products groups. Previously, Verhoef was with the liquid chromatography division and the DNA microarray business of Hewlett Packard/Agilent Technologies. He holds a BS degree in medical microbiology and biochemistry from the Van’t Hoff Institute in Rotterdam, the Netherlands.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.